

4. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. *In situ* retroviral-mediated gene transfer for the treatment of brain tumors in rats. *Cancer Res.* 1993;53:83–88.
5. Serman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. *Hum Gene Ther.* 1998;9:1083–1092.
6. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. *Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther.* 1998;9:2595–2604.
7. Shand N, Weber F, Mariani L, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. *Hum Gene Ther.* 1999;10:2325–2335.
8. Morris JC, Ramsey WJ, Wildner O, et al. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. *Hum Gene Ther.* 2000;11:487–503.
9. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. *Curr Gene Ther.* 2003;3:13–26.
10. Okada T, Caplen NJ, Ramsey WJ, et al. *In situ* generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy *in vitro* and *in vivo*. *J Gene Med.* 2004;6:288–299.
11. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. *Proc Natl Acad Sci USA.* 1996;93:1831–1835.
12. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. *Cancer Res.* 2000;60:3989–3999.
13. Matono S, Tanaka T, Sueyoshi S, Yamana H, Fujita H, Shirouzu K. Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer. *Int J Oncol.* 2003;23:1309–1315.
14. Okada Y, Okada N, Nakagawa S, et al. Tumor necrosis factor α -gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors. *Jpn J Cancer Res.* 2002;93:436–444.
15. Okada Y, Okada N, Nakagawa S, et al. Fiber-mutant technique can augment gene transduction efficacy and antitumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors. *Cancer Lett.* 2002;177:57–63.
16. Okada Y, Okada N, Mizuguchi H, et al. Optimization of antitumor efficacy and safety of *in vivo* cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. *Biochim Biophys Acta.* 2004;1670:172–180.
17. Mizuguchi H, Hayakawa T. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. *Cancer Gene Ther.* 2002;9:236–242.
18. Okada Y, Okada N, Mizuguchi H, Hayakawa T, Mayumi T, Mizuno N. An investigation of adverse effects caused by the injection of high-dose TNF α -expressing adenovirus vector into established murine melanoma. *Gene Therapy.* 2003;10:700–705.
19. van der Eb MM, Cramer SJ, Vergouwe Y, et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. *Gene Therapy.* 1998;5:451–458.
20. Brand K, Loser P, Arnold W, Bartels T, Strauss M. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. *Gene Therapy.* 1998;5:1363–1371.
21. Bustos M, Sangro B, Alzuguren P, et al. Liver damage using suicide genes. A model for oval cell activation. *Am J Pathol.* 2000;157:549–559.
22. Hearing VJ, Jimenez M. Analysis of mammalian pigmentation at the molecular level. *Pigment Cell Res.* 1989;2:75–85.
23. Hearing VJ, Tsukamoto K. Enzymatic control of pigmentation in mammals. *FASEB J.* 1991;5:2902–2909.
24. Gu J, Kagawa S, Takakura M, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. *Cancer Res.* 2000;60:5359–5364.
25. Koga S, Hirohata S, Kondo Y, et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. *Hum Gene Ther.* 2000;11:1397–1406.
26. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. *Gene Therapy.* 2002;9:30–37.
27. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. *Cancer Res.* 2003;63:3181–3188.
28. Kolquist KA, Ellisen LW, Counter CM, et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. *Nat Genet.* 1998;19:182–186.
29. Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. *Cancer Res.* 1999;59:551–557.
30. Braunstein I, Cohen-Barak O, Shachaf C, et al. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells. *Cancer Res.* 2001;61:5529–5536.
31. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved *in vitro* ligation method. *Hum Gene Ther.* 1998;9:2577–2583.
32. Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. *Hum Gene Ther.* 1999;10:2013–2017.
33. Mizuguchi H, Koizumi N, Hosono T, et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. *Gene Therapy.* 2001;8:730–735.
34. Park BJ, Brown CK, Hu Y, et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. *Hum Gene Ther.* 1999;10:889–898.

35. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983;65:55–63.
36. Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. *Hum Gene Ther*. 1998;9:2363–2373.
37. McCart JA, Wang ZH, Xu H, et al. Development of a melanoma-specific adenovirus. *Mol Ther*. 2002;6:471–480.

UNCORRECTED PROOF

Comparison of Transgene Expression Mediated by Several Fiber-Modified Adenovirus Vectors in Trophoblast Cells

N. Koizumi^a, M. Kondoh^a, H. Mizuguchi^b, T. Nakanishi^c, A. Masuyama^a,
F. Ida^a, M. Fujii^a, T. Hayakawa^d, E. Nakashima^e, K. Tanaka^c and Y. Watanabe^{a,*}

^a Department of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan; ^b Project III, National Institute of Health Sciences, Osaka Branch, Fundamental Research Laboratories for Development of Medicine, Osaka 567-0085, Japan; ^c Department of Toxicology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; ^d National Institute of Health Sciences, Tokyo 158-8501, Japan; ^e Department of Pharmaceutics, Kyoritsu University of Pharmacy, Tokyo 105-8512, Japan

Paper accepted 13 October 2004

The transfer of genes of interest is a useful method for studying placental biology. Recombinant adenovirus (Ad) vector is an efficient vector for transgene expression. An interaction between the fiber of Ad and the coxsackievirus and adenovirus receptor on the cell membrane is the first step in infection. We previously developed fiber-modified Ad vectors and showed that they improved transgene activity in several cell lines when compared to wild-type vector. In the present study, we examined the ability of three fiber-modified Ad vectors to transduce human choriocarcinoma cell lines (JEG-3, JAR and BeWo) and rat trophoblast cell lines (Rcho-1, TR-TBT 18d-1 and TR-TBT 18d-2). We compared the transgene efficacy of wild-type Ad-L2 vector, Ad-RGD(HI)-L2 vector containing an Arg-Gly-Asp motif, Ad-K7(C)-L2 vector containing a 7-tandem lysine motif, and Ad-RGD(HI)K7(C)-L2 vector containing both motifs in the fiber. We used the luciferase gene as a reporter gene. In the human and rodent trophoblast cell lines, Ad-RGD(HI)-L2 had the greatest infectious potential, followed by Ad-RGD(HI)K7(C)-L2, Ad-K7(C)-L2 and Ad-L2. Compared to the amount of luciferase produced by wild-type vector, Ad-RGD(HI)-L2 mediated 8.1-fold the amount of luciferase in JEG-3 cells, 13.5-fold in JAR cells, 76.8-fold in BeWo cells, 5.0-fold in Rcho-1, 19.4-fold in TR-TBT 18d-1 and 15.0-fold in TR-TBT 18d-2. These results indicate that Ad-RGD(HI) is a potential recombinant Ad vector for transgene expression in some trophoblast cell lines.

Placenta (2005), 26, 729–734

© 2004 Elsevier Ltd. All rights reserved.

Keywords: Adenovirus vector; Fiber; Gene delivery; Trophoblast

Abbreviations: Ad, adenovirus; HSV, herpes simplex virus; AAV, adeno-associated vector; SV, sindbis vector; CAR, coxsackievirus and adenovirus receptor; RT, reverse transcription; PCR, polymerase chain reaction; RT-PCR, reverse transcription–polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase

INTRODUCTION

A technique to transfer genes to trophoblasts may be useful to study the biological functions of placenta. It is important to identify an appropriate vector system to deliver target genes to trophoblast cells. Recombinant virus vectors are powerful systems to transduce genes into trophoblasts [1]. The transduction of genes into trophoblasts has been mediated by adenovirus (Ad) vectors, herpes simplex virus (HSV) vectors,

adeno-associated virus vectors and sindbis virus (SV) vectors [1]. The binding of vector to ligand on the cell surface is the first step in infection. Coxsackievirus and adenovirus receptor (CAR) is a ligand for Ad vector, proteoglycan is a receptor for HSV vector, and laminin is a receptor for SV vectors [1]. Since Ad vectors are easy to prepare and have a high infectious efficacy, they may be potential vectors for transducing genes into trophoblasts. But, CAR is not expressed in some trophoblast cells, making it difficult to transduce these cells with Ad vectors [2–4]. An initial step of infection with Ad virus is the interaction of the knob domain of the fiber on Ad virus with CAR on the targeted cells [5,6]. Therefore, modulation of the knob domain on Ad vectors may expand their tropism.

* Corresponding author. Tel.: +81 42 721 1555; fax: +81 42 723 3585.

E-mail address: watanabe@ac.shoyaku.ac.jp (Y. Watanabe).

To overcome the limited tropism of Ad vectors, our group and other groups have developed mutated Ad vectors that contain a modulated knob domain in the fiber. The Ad-RGD(HI)-L2 vector, which contains the RGD motif in the knob domain of the fiber, can transduce cells by binding to α v-integrin on the cell surface. The Ad-RGD(HI)-L2 vector has expanded tropism against CAR-negative human and murine cells [7–15]. The Ad-K7(C)-L2 vector, which has a 7-tandem lysine peptide, can infect cells via heparan sulfate on the cell surface [7,9–11,15–18]. Recently, the Ad-RGD(HI)K7(C)-L2 vector, which contains RGD and K7 in the fiber knob, was developed [15,19]. We found that the efficacy of transgene delivery mediated by Ad-RGD(HI)-L2, Ad-K7(C)-L2 and Ad-RGD(HI)K7(C)-L2 varied among different cell lines [15]. For example, the Ad-RGD(HI)K7(C)-L2 and Ad-K7(C)-L2 vectors efficiently delivered transgenes into rat skeletal muscle myoblast L6 cells and rat liver epithelial cells, respectively. Thus, it is important to select an Ad vector system that is suitable for a particular cell line.

To the best of our knowledge, there are only two rat trophoblast cell lines, Rcho-1 cells and TR-TBT (18d-1 and 18d-2) cells. Cultured Rcho-1 cells differentiate into trophoblast giant cells, which play an important role in endocrinology of the rat placenta [20]. Therefore, Rcho-1 cells have been widely used for analysis of differentiation in the placenta [20–23]. TR-TBT 18d-1 and 18d-2 cells are syncytiotrophoblast cells that were established by Kitano and colleagues [24]. There are two syncytiotrophoblast layers in the labyrinth zone of the placenta. TR-TBT 18d-1 and 18d-2 cells are syncytiotrophoblasts in layer I and layer II, respectively. Thus, TR-TBT cells are also useful models of trophoblasts in vitro. In the present study, we compared the efficacy of transgene delivery mediated by wild-type Ad-L2, Ad-RGD(HI)-L2, Ad-K7(C)-L2 and Ad-RGD(HI)K7(C)-L2 in well-used human trophoblast cell lines as an in vitro model (JEG-3, JAR and BeWo cells) and rat trophoblast cell lines (Rcho-1, TR-TBT 18d-1 and 18d-2).

MATERIALS AND METHODS

Cells

The human trophoblast cell line BeWo clone (b30) was kindly provided by Dr. A. Schwartz (Washington University, MO, USA). BeWo cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% heat-inactivated fetal

bovine serum (FBS) containing 1% MEM non-essential amino acid solution (Gibco, MD, USA), 1.6 g/l sodium bicarbonate, 0.584 g/l L-glutamine, 3.5 g/l D-glucose, 100 μ g/ml penicillin G, 100 μ g/ml streptomycin and 50 μ g/ml gentamicin. Human trophoblast JAR and JEG-3 cells were cultured with minimum essential Eagle's medium with 10% FBS and RPMI-1640 with 10% FBS, respectively. Rat trophoblast Rcho-1 and TR-TBT (18d-1, 18d-2) were cultured in RPMI-1640 and DMEM supplemented with 10% FBS, respectively.

Preparation of wild-type Ad vectors and the fiber-modified Ad vectors

We used wild-type Ad vector, Ad-L2, and three types of fiber-modified Ad vectors, Ad-RGD(HI)-L2, Ad-K7(C)-L2 and Ad-RGD(HI)K7(C)-L2 (Table 1). Ad-RGD(HI)-L2 contains RGD peptide in the HI loop of the fiber knob, Ad-K7(C)-L2 contains K7 peptide in the C-terminal of the fiber knob, and Ad-RGD(HI)K7(C)-L2 contains RGD and K7 peptides in the HI loop and the C-terminal of the fiber knob, respectively [14,15,25,26]. These Ad vectors were prepared by ultracentrifugation in CsCl gradient [25,26]. The virus particle titer and infectious (plaque forming unit: PFU) titer were calculated by the methods of Maizel et al. [27] and Kanegae et al. [28], respectively. The particle-to-PFU ratio and foreign peptide sequence (core sequence is bold letters) of each vector is shown in Table 1.

Adenovirus-mediated gene transduction into cultured cells

Cells (1×10^4) were seeded onto a 96-well dish. On the following day, they were transduced with 300 vector particles per cell of Ad-L2, Ad-RGD(HI)-L2, Ad-K7(C)-L2 or Ad-RGD(HI)-K7(C)-L2 for 1.5 h. After culture for 48 h, the luciferase production was measured using a commercially available luciferase assay kit as follows (PicaGene LT2.0, Toyo Inki Co., Ltd., Tokyo, Japan). Luminescence was converted to luciferase production using luciferase protein as a standard, and the production of luciferase was corrected by the number of cells.

RT-PCR analysis

There are two main steps in Ad infection: (1) binding of the fiber knob on Ad to a ligand on the cell membrane, followed by (2) the interaction between the RGD motif on Ad with

Table 1. Ad vectors used in this study

Ad vectors	Foreign peptide		Particle-to-PFU ratio (PT/PFU)
	HI loop	C-terminal	
Ad-L2	—	—	14
Ad-RGD(HI)-L2	CDCRGDCFC	—	21
Ad-K7(C)-L2	—	(GS) ₄ KKKKKKK	75
Ad-RGD(HI)K7(C)-L2	CDCRGDCFC	(GS) ₄ KKKKKKK	32

$\alpha v\beta 3$ - and $\alpha v\beta 5$ -integrins on the cell membrane [5,29]. Therefore, we examined the expression of CAR, αv -integrin, $\beta 3$ -integrin and $\beta 5$ -integrin in human and rat trophoblast cell lines by RT-PCR analysis. Total RNA was isolated using TRIZOL reagent (Life Technologies, Tokyo, Japan). Reverse transcription (RT) was performed using a TaKaRa RNA PCR kit (AMV) Ver. 2.1 for first strand cDNA synthesis (TaKaRa Bio, Osaka, Japan) according to the instructions of the manufacturer. After the RT reaction, the rat/human CAR and integrins (αv , $\beta 3$ and $\beta 5$) were amplified by PCR. The primers and the expected size of the PCR product are summarized in Table 2. PCR conditions were as follows: human CAR, 30 s at 94 °C, 60 s at 65 °C, and 120 s at 72 °C for 30 cycles; human αv -integrin, 40 s at 94 °C, 60 s at 65 °C, and 120 s at 72 °C for 40 cycles; human $\beta 3$ -integrin, 30 s at 94 °C, 40 s at 65 °C, and 60 s at 72 °C for 30 cycles; human $\beta 5$ -integrin, 40 s at 94 °C, 40 s at 58 °C, and 60 s at 72 °C for 20 cycles; human β -actin, 30 s at 94 °C, 30 s at 60 °C, and 30 s at 72 °C for 35 cycles; rat CAR, 45 s at 94 °C, 60 s at 53 °C, and 90 s at 72 °C for 40 cycles; rat αv -integrin, 45 s at 94 °C, 60 s at 57 °C, and 90 s at 72 °C for 30 cycles; rat $\beta 3$ -integrin, 45 s at 94 °C, 60 s at 58 °C, and 90 s at 72 °C for 30 cycles; rat $\beta 5$ -integrin, 45 s at 94 °C, 60 s at 53 °C, and 90 s at 72 °C for 40 cycles; and rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 45 s at 94 °C, 60 s at 60 °C, and 90 s at 72 °C for 40 cycles.

PCR products were electrophoresed in a 2.0% agarose gel. To ensure the quality of the procedure, RT-PCR was also performed using specific primers for β -actin and GAPDH.

Statistical analysis

The significant difference was calculated using one-way ANOVA followed by Dunnett's test.

RESULTS

Human trophoblast cells

As shown in Figure 1, CAR and αv -integrin were expressed in all of the trophoblast cell lines. $\beta 3$ -Integrin expression was not detected in JEG-3 cells, and $\beta 5$ -integrin expression was not observed in BeWo cells.

Next, we compared the efficacy of gene transfer mediated by Ad-L2, Ad-RGD(HI)-L2, Ad-K7(C)-L2 and Ad-RGD(HI)K7(C)-L2 vectors in three cell lines, JAR, JEG-3 and BeWo. Although every combination of vector and cell line resulted in luciferase production, the amount of luciferase varied markedly (Figure 2). The greatest amount of luciferase was produced by the Ad-RGD(HI)-L2 vector. When compared to Ad-L2, Ad-RGD(HI)-L2 mediated the production of 8.1-fold the amount of luciferase in JEG-3 cells, 13.5-fold the amount in JAR cells, and 76.8-fold the amount in BeWo cells. The second highest amounts of luciferase were mediated by the Ad-RGD(HI)K7(C)-L2 vector. When compared to Ad-L2, Ad-RGD(HI)K7(C)-L2 mediated the production of 4.2-fold the amount of luciferase in JAR cells, 6.2-fold in JEG-3 cells, and 9.4-fold in BeWo cells. Modification of K7 in the fiber knob domain did not result in increased luciferase production in JAR cells and JEG-3

Table 2. Primers for RT-PCR analysis

Gene		Sequence (5' to 3')	Parameter (°C)	Expected size (bp)
Human CAR	Forward	AGCCTTCAGGTGCGAGATGTTACG	65	366
	Reverse	TAGGACAGCAAAAAGATGATAAGAC		
Human αv -integrin	Forward	GCCTATCTCCACGCACACTG	65	287
	Reverse	TTGGACCATTGTTTCTCAGC		
Human $\beta 3$ -integrin	Forward	GAGGATGACTGTGTCTCGTCAG	65	232
	Reverse	CTGGCGCGTTCCTCCTCAA		
Human $\beta 5$ -integrin	Forward	GCCTATCTCCACGCACACTG	58	454
	Reverse	AGACTCCGACCCTTCCTGAC		
Human β -actin	Forward	CAAGAGATGGCCACGGCTGCT	60	275
	Reverse	TCCTTCTGCATCCTGTCGGCA		
Rat CAR	Forward	ATGGATCCTACACCCGAACAGAGGATCG	53	280
	Reverse	GCGAATTCGCGTCGCCAGACTTGACAT		
Rat αv -integrin	Forward	GCCTATCTCCACGCACACTG	57	273
	Reverse	CGGGTGCTATCTGTCTTATG		
Rat $\beta 3$ -integrin	Forward	TAATGATGGGCGCTGCCACA	58	279
	Reverse	CGTAAGCATCAACGATGAGC		
Rat $\beta 5$ -integrin	Forward	TGTGTCTCTGCGGTGTTTGC	53	312
	Reverse	CCACGAGAACACCACAACAA		
Rat GAPDH	Forward	ACCACAGTCCATGCCATCAC	60	452
	Reverse	TCCACCACCCTGTTGCTGTA		




Figure 1. RT-PCR analysis of CAR and integrin (α_v , β_3 , β_5) and β -actin expression in human trophoblast cell lines.

cells. But, as compared to Ad-L2 vector, the modification of K7 elevated the luciferase production by 4.6-fold in BeWo cells.

Rat trophoblast cells

Next, we investigated the effects of different Ad vectors on transgene expression in Rcho-1 cells and TR-TBT (18d-1 and




Figure 2. Luciferase production in human trophoblast cell lines transduced by Ad-L2, Ad-RGD(HI)-L2, Ad-K7(C)-L2 or Ad-RGD(HI)-K7(C)-L2. Cells were transduced with 300 vector particles per cell for 1.5 h. A luminescent assay was used to measure luciferase production after 48 h of culture. Data are expressed as mean \pm S.D. ($n = 4$). Significant difference is observed among the groups with different letters ($p < 0.01$).




Figure 3. RT-PCR analysis of CAR and integrin (α_v , β_3 , β_5) and GAPDH expression in rat trophoblast cell lines.

18d-2) cells. RT-PCR analysis revealed that mRNA for CAR, α_v -integrin, β_3 -integrin and β_5 -integrin is expressed in each rat trophoblast cell line (Figure 3). We studied the gene transfer activities mediated by the Ad-RGD(HI), Ad-K7(C)-L2 and Ad-RGD(HI)K7(C)-L2 vectors in rat trophoblast cell lines. When compared to Ad-L2 vector, Ad-RGD(HI)-L2 mediated the production of 5–20 times more luciferase (Figure 4). Ad-K7(C)-L2 caused decreased luciferase production when compared to Ad-L2 vectors (34% in Rcho-1, 43% in TR-TBT 18d-1 and 56% in TR-TBT 18d-2). Ad-RGD(HI)K7(C)-L2-mediated gene transfer resulted in increased luciferase production when compared with Ad-L2 vectors, but the production of luciferase was lower than that mediated by Ad-RGD(HI)-L2.

DISCUSSION

The first step in Ad infection is the binding of the fiber knob of Ad with CAR on the cell membrane [5,6]. Since the HI loop and C-terminus of the fiber are not involved in formation of the CAR-binding site [30–32], we developed fiber-modified Ad vectors with expanded tropism by insertion of the RGD motif and/or K7 motif into the HI loop and/or the C-terminus of the fiber [12,15,33]. In the present study, we evaluated the ability of several fiber-modified Ad vectors to transduce human and rat trophoblast cell lines. We found that Ad-RGD(HI) vector, which contains an RGD motif in the fiber knob, is the prominent vector system for transduction of human and rat trophoblast cell lines.

In human trophoblast cell lines, Ad-RGD(HI)-L2 was the most efficient vector, Ad-RGD(HI)K7(C)-L2 had moderate efficiency, and Ad-K7(C)-L2 and Ad-L2 were the least




Figure 4. Luciferase production in rat trophoblast cells transduced by Ad-L2, Ad-RGD(HI)-L2, Ad-K7(C)-L2 or Ad-RGD(HI)-K7(C)-L2. Cells were transduced with 300 vector particles per cell for 1.5 h. A luminescent assay was used to measure luciferase production after 48 h of culture. Data are expressed as mean \pm S.D. ($n = 4$). Significant difference is observed among the groups with different letters ($p < 0.01$).

efficient. Although Ad-K7(C)-L2 mediated greater luciferase production than Ad-L2 in JAR and BeWo cells, the transgene effects of Ad-RGD(HI)K7(C)-L2 were weak (rather than

additive) when compared to Ad-RGD(HI)-L2 and Ad-K7(C)-L2. The RGD motif contains a positively charged arginine (R) residue. Thus, the lower efficiency of Ad-RGD(HI)K7(C)-L2 vector may be caused by a disturbance in the interaction of the fiber with the ligand on the membrane by the positively charged K7 motif in JAR and BeWo cells. In spite of the absence of $\beta 3$ -integrin expression, the transgene effect of Ad-RGD(HI)-L2 was observed in JEG-3 cells. We found that expression of $\beta 3$ -integrin was not responsible for transgene activity of Ad-RGD(HI)-L2 in mouse fibroblast L cells and human glioma LN444 cells [12]. So, Ad-RGD(HI)-L2 in JEG-3 may infect JEG-3 cells via an $\alpha v \beta 5$ -integrin-dependent pathway. Ad-RGD(HI)-L2 was also the most promising vector for transgene expression in rat trophoblast cell lines. The transducing efficiency in rat trophoblast cell lines was not increased by the insertion of the K7 motif in the fiber knob. This suggests that interaction between heparan sulfate on the cell membrane and the fiber containing the K7 motif did not contribute to infection with Ad vector. The lower transgene efficiency mediated by the insertion of the RGD motif and K7 motif in the knob of the fiber (as compared to the insertion of only the RGD motif) may be caused by positively charged K7 disturbing the interaction between the RGD motif and integrin. Dmitriev et al. [8] reported that the RGD motif of the penton base of Ad does not contribute to the binding to $\alpha v \beta 3$ -integrin on the cell membrane. Ad-RGD(HI) may effectively infect trophoblast cells in the RGD motif in a fiber-dependent fashion.

In summary, fiber-modified Ad that contains the RGD motif in the fiber knob is a promising vector for gene transfer to human and rat trophoblast cell lines. This is the first report to compare the gene transfer activity of various recombinant Ad vectors in trophoblast cell lines. Our findings will be useful for future clinical and basic research regarding the placenta.

ACKNOWLEDGEMENT

We thank Dr. M. J. Soares (University of Kansas Medical Center) for kindly providing us Recho-1 cells. This work was supported by a Grants-in-Aid for Scientific Research (C) (No. 15590139) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

REFERENCES

- [1] Parry S, Koi H, Strauss III JF. Transplacental drug delivery: gene and virus delivery to the trophoblast. *Adv Drug Deliv Rev* 1999;38:69–80.
- [2] MacCalman CD, Furth EE, Omigbodun A, Kozarsky KF, Coutifaris C, Strauss III JF. Transduction of human trophoblast cells by recombinant adenovirus is differentiation dependent. *Biol Reprod* 1996;54:682–91.
- [3] Koi H, Zhang J, Makrigiannakis A, Getsios S, MacCalman CD, Kopf GS, et al. Differential expression of the coxsackievirus and adenovirus receptor regulates adenovirus infection of the placenta. *Biol Reprod* 2001;64:1001–9.
- [4] Parry S, Holder J, Halterman MW, Weitzman MD, Davis AR, Federoff H, et al. Transduction of human trophoblastic cells by replication deficient recombinant viral vectors. *Am J Pathol* 1998;152:1521–9.
- [5] Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. *Science* 1997;275:1320–3.
- [6] Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. *Proc Natl Acad Sci U S A* 1997;94:3352–6.
- [7] Wickham TJ, Tzeng E, Shears 2nd LL, Roelvink PW, Li Y, Lee GM, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. *J Virol* 1997;71:8221–9.
- [8] Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus. *J Virol* 1998;72:9706–13.
- [9] Hidaka C, Milano E, Leopold PL, Bergelson JM, Hackett NR, Finberg RW, et al. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. *J Clin Invest* 1999;4:579–87.
- [10] Staba MJ, Wickham TJ, Kovacs I, Hallahan DE. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. *Cancer Gene Ther* 2000;7:13–9.
- [11] Hay CM, De Leon H, Jafari JD, Jakubczak JL, Mech CA, Hallenbeck PL, et al. Enhanced gene transfer to rabbit jugular veins by

- an adenovirus containing a cyclic RGD motif in the HI loop of the fiber knob. *J Vasc Res* 2002;38:315–23.
- [12] Koizumi N, Mizuguchi H, Hosono T, Ishii-Watabe A, Uchida E, Utoguchi N, et al. Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. *Biochem Biophys Acta* 2001;1568:13–20.
- [13] Okada N, Tsukada Y, Nakagawa S, Mizuguchi H, Mori K, Saito T, et al. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. *Biochem Biophys Res Commun* 2001;282:173–9.
- [14] Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA, et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. *Gene Ther* 2001;8:730–5.
- [15] Koizumi N, Mizuguchi H, Utoguchi N, Watanabe Y, Hayakawa T. Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. *J Gene Med* 2003;5:267–76.
- [16] Bouri K, Feero WG, Myerburg MM, Wickham TJ, Kovcsdi I, Hoffman EP, et al. Poly-lysine modification of adenoviral fiber protein enhances muscle cell transduction. *Hum Gene Ther* 1999;10:1633–40.
- [17] Gonzalez R, Verecque R, Wickham TJ, Facon T, Hetuin D, Kovcsdi I, et al. Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells. *Hum Gene Ther* 1999;10:2709–17.
- [18] Gonzalez R, Verecque R, Wickham TJ, Vanrumbeke M, Kovcsdi I, Bauters F, et al. Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. *Gene Ther* 1999;6:314–20.
- [19] Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, Han T, et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus–adenovirus receptor-independent gene transfer efficiency. *Hum Gene Ther* 2002;13:1647–53.
- [20] Yamamoto T, Roby KF, Kwok SC, Soares MJ. Transcriptional activation of cytochrome P450 side chain cleavage enzyme expression during trophoblast cell differentiation. *J Biol Chem* 1994;269:6517–23.
- [21] Hamlin GP, Soares MJ. Regulation of deoxyribonucleic acid synthesis in proliferating and differentiating trophoblast cells: involvement of transferrin, transforming growth factor- β , and tyrosine kinases. *Endocrinology* 1995;136:322–31.
- [22] Oda M, Sun W, Hattori N, Tanaka S, Shiota K. PAL31 expression in rat trophoblast giant cells. *Biochem Biophys Res Commun* 2001;287:721–6.
- [23] Ohgane J, Hattori N, Oda M, Tanaka S, Shiota K. Differentiation of trophoblast lineage is associated with DNA methylation and demethylation. *Biochem Biophys Res Commun* 2002;290:701–6.
- [24] Kitano T, Iizasa H, Terasaki T, Asashima T, Matsunaga N, Utoguchi N, et al. Polarized glucose transporters and mRNA expression properties in newly developed rat syncytiotrophoblast cell lines, TR-TBTs. *J Cell Physiol* 2002;193:208–18.
- [25] Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. *Hum Gene Ther* 1998;9:2577–83.
- [26] Mizuguchi H, Kay MA. A simple method for constructing E1 and E1/E4 deleted recombinant adenovirus vector. *Hum Gene Ther* 1999;10:2013–7.
- [27] Maizel Jr JV, White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. *Virology* 1968;36:115–25.
- [28] Kanegae Y, Makimura M, Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. *Jpn J Med Sci Biol* 1994;47:157–66.
- [29] Wickham TJ, Filardo EJ, Cheresch DA, Nemerow GR. Integrin $\alpha\beta 5$ selectively promotes adenovirus mediated cell membrane permeabilization. *J Cell Biol* 1994;127:257–64.
- [30] Xia D, Henry LJ, Gerard RD, Deisenhofer J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 Å resolution. *Structure* 1994;2:1259–70.
- [31] Kirby I, Davison E, Beavil AJ, Soh CP, Wickham TJ, Roelvink PW, et al. Modulation in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. *J Virol* 1999;73:9508–14.
- [32] Kirby I, Davison E, Beavil AJ, Soh CP, Wickham TJ, Roelvink PW, et al. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. *J Virol* 2000;74:2804–13.
- [33] Mizuguchi H, Koizumi N, Hosono T, Ishii-Watabe A, Uchida E, Utoguchi N, et al. CAR- or α integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. *Gene Ther* 2002;9:769–76.



PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability

Yusuke Eto^{1†}
Jian-Qing Gao^{1,2†}
Fumiko Sekiguchi¹
Shinnosuke Kurachi¹
Kazufumi Katayama¹
Mitsuko Maeda⁴
Koichi Kawasaki⁴
Hiroyuki Mizuguchi³
Takao Hayakawa³
Yasuo Tsutsumi³
Tadanori Mayumi⁴
Shinsaku Nakagawa^{1*}

¹Graduate School of Pharmaceutical Sciences, Osaka University, Japan

²College of Pharmaceutical Sciences, Zhejiang University, P.R. China

³National Institute of Health Sciences, Japan

⁴School of Pharmaceutical Sciences, Kobe Gakuin University, Japan

*Correspondence to:
Shinsaku Nakagawa, Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, Yamadaoka 1-6, Suita City, Osaka 565-0871, Japan.
E-mail:
nakagawa@phs.osaka-u.ac.jp

†These authors contributed equally to this work.

Abstract

Background PEGylation of adenovirus vectors (Ads) is an attractive strategy in gene therapy. Although many types of PEGylated Ad (PEG-Ads), which exhibit antibody evasion activity and long plasma half-life, have been developed, their entry into cells has been prevented by steric hindrance by polyethylene glycol (PEG) chains. Likewise, sufficient gene expression for medical treatment could not be achieved.

Methods A set of PEG-Ads, which have different PEG modification rates, was constructed, and gene expression was evaluated using A549 cells. A novel PEGylated Ad (RGD-PEG-Ad), which contained RGD (Arg-Gly-Asp) peptides on the tip of PEG, was developed. We evaluated gene expression both in Coxsackie-adenovirus receptor (CAR)-positive as well as -negative cells, and *in vivo* gene expression was also determined. Furthermore, the antibody evasion ability and the specificity of infection exhibited by this RGD-PEG-Ad were also evaluated.

Results Whereas PEG-Ads decreased gene expression in CAR-positive cells, RGD-PEG-Ad enhanced gene expression notably, to a level about 200-fold higher than that of PEG-Ads. Moreover, gene expression of RGD-PEG-Ad was almost equal to that of Ad-RGD, which contains an RGD-motif in the fiber and exhibits among the highest gene expression of CAR-positive and -negative cells. Furthermore, although Ad-RGD gene expression decreased remarkably in the presence of anti-Ad antiserum, RGD-PEG-Ad maintained its activity against antibodies. *In vivo* experiments also demonstrated that the modification of Ads with RGD-PEG induced efficient gene expression.

Conclusions In the present study, we demonstrated that a new strategy, which combined integrin-targeting the RGD peptide on the tip of PEG and modified the Ad using this material, could enhance gene expression in both CAR-positive and -negative cells. At the same time, this novel PEGylated Ad maintained strong protective activity against antibodies. This strategy could also be easily modified for developing other vectors using other targeting molecules. Copyright © 2004 John Wiley & Sons, Ltd.

Keywords adenovirus; antibody; polyethylene glycol; RGD peptide; gene expression

Introduction

Gene therapy for cancer or other incurable diseases has attracted considerable attention. The major obstacle to widespread utilization of gene therapy

Received: 14 June 2004
Revised: 2 September 2004
Accepted: 2 September 2004

involves the transgenic vector. Adenovirus vectors (Ads) exhibit high transduction efficiency and gene expression, and can efficiently transfer genes into both dividing and non-dividing cells. Therefore, they are widely used as vectors for gene therapy [1–4]. On the other hand, many people carry neutralizing antibodies to Ads, and the administration of a large amount of Ads may cause side effects. Therefore, clinical application of Ads is difficult [5,6], and many studies have been conducted in an attempt to overcome the limitations of Ads [7–9].

PEGylation, the covalent attachment of activated monomethoxy polyethylene glycol to free lysine groups on the surface of an Ad, is a promising strategy for overcoming these limitations. PEGylation of therapeutic proteins such as cytokines has been reported previously [10,11], and several groups have reported that PEGylated adenovirus exhibits several advantageous attributes [12–14]. Without the need for modifying Ad capsid protein by genetic recombination, a PEGylated Ad (PEG-Ad) can transduce its therapeutic gene into cells even in the presence of Ad-neutralizing antibodies [15,16], and extend residence time in the blood [17]. Furthermore, targeting of PEG-Ads has also been attempted. Lanciotti *et al.* reported targeting Ads using heterofunctional PEG, tresyl-PEG-maleimide [18]. Conjugation of optimized fibroblast growth factor 2 (FGF2), which possesses monoreactive cysteine, to the maleimide group on PEG-Ad was mediated by a reactive sulfhydryl group on the surface of the protein. Ogawara *et al.* reported enhanced transgene delivery to activated vascular endothelial cells using a PEG-Ad combined with an antibody on the tip of PEG [19]. These reports suggest that the use of a functional molecule on the tip of PEG can efficiently change the tropism of Ads or PEG-Ads.

In the present study, we attempted to overcome the previously observed reduction in gene expression caused by the inhibition of endocytosis through the Coxsackie-adenovirus receptor (CAR). This inhibition is due to steric hindrance by the PEG chains and has prevented the widespread therapeutic use of PEG-Ads. Therefore, we developed a new versatile Ad that maintained the positive attributes of PEGylation but also exhibited high transduction efficiency both in CAR-positive and -negative cells.

Infection by Ads occurs in two distinct steps. In the first step, the fiber protein of the Ad binds to its CAR [20–22], and the transduction efficiency of this step is influenced by the amount of CAR present. Following this, internalization via receptor-mediated endocytosis is promoted when the RGD motif of the penton bases combines with $\alpha v\beta 3$ and $\alpha v\beta 5$ integrins [23,24], which are present on many types of cells. We focused on the second step of Ad infection and constructed PEG with RGD peptides on the tip. The PEGylated Ad (RGD-PEG-Ad), which contained RGD peptide on the tip of PEG, was expected to show high transduction efficiency for both CAR-positive and -negative cells because of the interaction between RGD and integrin. Likewise, RGD-PEG-Ad possesses the ability to avoid neutralizing antibodies, a major advantage of

PEGylation [15,16]. Incidentally, an Ad that contains an RGD peptide in the HI loop of the fiber (Ad-RGD) has already been developed, and this vector exhibits the highest transduction efficiency via integrin [25,26].

In the present study, we constructed several PEG-Ads at various PEG modification rates, and measured their gene expression. Following this, we used Lipofectamine to determine whether PEG-Ads possessed high gene expression ability. This verified that, upon entering a cell, PEG-Ad expressed the gene originating from the Ad itself. In the next step, we constructed RGD-PEG-Ad and measured its gene expression in CAR-positive and -negative cells with or without Ad antiserum.

Materials and methods

Cell lines

A549 (human lung carcinoma) cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS). B16BL6 (mouse melanoma) cells were cultured in minimum essential medium supplemented with 7.5% FCS.

Development of adenovirus vectors

In this study, all experiments used E1-deleted Ad type 5, which expressed firefly luciferase under the control of cytomegalovirus (CMV) promoters. Both conventional and RGD fiber mutant Ads were amplified in 293 cells using a modification of established methods, purified from cell lysates by banding twice through CsCl gradients, dialyzed and stored at -80°C . The Ads used in this study were constructed by an improved *in vitro* ligation method as described previously [27]. Determination of virus particle titer was accomplished spectrophotometrically by the methods of Maizel *et al.* [28].

Preparation of RGD-PEG

The synthetic scheme for RGD-PEG is shown in Figure 3. *N*-(9-Fluorenylmethoxycarbonyl)-*O*-(succinimidyl)- ω -amino- α -carboxy-PEG (Fmoc-PEG-NHS, MW 3400) was purchased from Shearwater Corporation (USA). β -Ala (β A) was used as a spacer between PEG and the RGD peptide. (Ac-YGGRGDTP β A)₂K-PEG- β AC-amide (RGD-PEG, MW 5500) was synthesized manually on a Rink amide resin [29] using a 9-fluorenylmethoxycarbonyl (Fmoc)-based solid-phase strategy. We employed 2(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and 1-hydroxybenzotriazole as coupling reagents, trityl (Trt) protection as the sulfhydryl group source, *tert*-butyl as the hydroxyl group source and 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) protection as the guanidinyll group source. To liberate the synthetic RGD-PEG from the resin, cleavage was achieved by using

a mixture of trifluoroacetic acid/triisopropylsilane/H₂O (95 : 2.5 : 2.5) [30] for 2 h at room temperature, followed by high-performance liquid chromatography (HPLC) purification on a C18 column. After addition of the peptide to *N*-(6-maleimidocaproyloxy)succinimide) (EMCS) in phosphate-buffered saline (PBS), pH 6.4, the solution was changed to pH 7.4 PBS and kept frozen at -80°C .

Covalent attachment of PEG to Ads

Activated methoxypolyethylene glycol-succinimidyl propionate (mPEG-SPA, MW 5000; Shearwater Corporation, USA) and RGD-PEG were used in this study. Ads were reacted with 25–6400-fold molar excess of mPEG-SPA to viral lysine residue at 37°C for 45 min with gentle stirring. Ads were also reacted with 250-fold molar excess of RGD-PEG under the same conditions. CsCl gradient ultracentrifugation was used for PEGylated adenovirus purification, and we assessed whether unmodified Ads were mixed with the PEGylated Ad. Modification ratio of PEGylated-Ads was determined by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-PAGE) analysis using NIH image software. SDS-PAGE was carried out, referring to the previous report by O'Riordan *et al.* [15], in a 4–20% polyacrylamide gel (PAG Mini 4/20; Daiichi Pure Chemicals, Japan). Viral protein (hexon) was stained by Coomassie brilliant blue. The PEGylated hexon band was separated from the unmodified hexon band. The ratios of each band were measured using NIH Image software, and the PEG modification ratio was calculated as described below, the band of PEGylated hexon/the band of PEGylated and unmodified hexon $\times 100$ [16]. After dilution in PBS, the particle sizes of Ads and RGD-PEG-Ad were measured using a Zetasizer 3000HS (Malvern Inc. UK).

Transduction efficiency of PEGylated Ads into A549 cells

A549 cells (2×10^4 cells/well) were seeded onto a 48-well plate. On the following day, the cells were transduced with 300, 1000, 3000, or 10 000 particles/cell of unmodified Ads and PEG-Ads that possessed various PEG modifications in a final volume of 500 μl in cell medium. After 24 h cultivation, luciferase activity was measured using the luciferase assay system (Promega, USA) and Microumat Plus LB 96 (Perkin Elmer, USA) after cells had been lysed with the luciferase cell culture lysis reagent (Promega, USA). Luciferase activity was calculated as relative light units (RLU)/well. In the presence of 20 $\mu\text{g}/\text{ml}$ Lipofectamine 2000 (Invitrogen, USA), A549 cells were transduced with 1000 particles/cell of unmodified Ads, 43%, 72%, and 89% modified PEG-Ads, heat-inactivated Ads, or heat-inactivated PEG-Ads, respectively. After 4 h, the virus solution was replaced with fresh medium, and the cells were incubated for 24 h. Subsequently, luciferase expression was measured using the method described above.

Transduction efficiency of RGD-PEG-Ad into A549 and B16BL6 cells

A549 and B16BL6 cells (2×10^4 cells/well) were seeded onto a 48-well plate. On the following day, the cells were transduced with 300, 1000, 3000, and 10 000 particles/cell of unmodified Ads, PEG-Ads, RGD-PEG-Ad or Ad-RGD, respectively, in a final volume of 500 μl in cell medium. After 24 h cultivation, luciferase activity was measured using the method described above.

Competition experiments using RGD peptide

B16BL6 cells (2×10^4 cells/well) were seeded onto a 48-well plate. On the following day, cells were incubated with RGD peptide (GRGDTP, SIGMA) at a final concentration of 200 $\mu\text{g}/\text{ml}$ for 10 min at room temperature, and then 3000 particles/cell of unmodified Ads, RGD-PEG-Ad or Ad-RGD were added to a final volume of 300 μl in cell medium. After 24 h cultivation, luciferase activity was measured using the method described above.

Preparation of Ad antiserum

Ad antiserum was obtained from ICR mice using methods previously reported by us and others [16,31]. In brief, a dose of 10^{10} particles of unmodified Ad containing Freund's complete adjuvant in 100 μl of PBS was administered hypodermically to a female ICR mouse (6 weeks old). Two to four weeks later, an additional dose of 10^{10} viral particles in Freund's incomplete adjuvant was hypodermically administered. Mouse serum was collected after 1 week, and stored at -20°C .

Antibody evasion by RGD-PEG-Ad in B16BL6 cells

B16BL6 cells (2×10^4 cells/well) were seeded onto a 48-well plate. On the following day, the cells were transduced with 1000 particles/cell of RGD-PEG-Ad or Ad-RGD in a final volume of 500 μl in cell medium in the presence or absence of 100 $\mu\text{l}/\text{well}$ Ad antiserum (42, 125 ng protein/well). After 24 h cultivation, luciferase activity was measured using the method described above.

Ad-mediated gene transduction *in vivo*

Unmodified Ad, Ad-RGD, and RGD-PEG-Ad (1.5×10^{10} particles/100 μl) were intravenously injected into BALB/c mice (female, 6 weeks old; obtained from Nippon SLC, Kyoto, Japan). Forty-eight hours later, organs were isolated and homogenized as previously described [32]. Luciferase activity was measured using the method described above.

Statistical analysis

Student's t-test was used for statistical comparison when applicable. Differences were considered statistically significant at $P \leq 0.05$.

Results

Transduction efficiency of Ads declines in response to PEGylation

We confirmed the feasibility of constructing PEG-Ads that exhibit various PEG modification rates, which are regulated by the amount of PEG made available for the reaction (data not shown). In the present study, Ads were reacted with 25-, 100-, 400-, 1600- and 6400-fold molar excesses of PEG relative to viral lysine residue. The results showed that the transduction efficiency of PEG-Ads fell remarkably as the PEG modification rate increased (Figure 1). Luciferase expression of the 34% modified PEG-Ad was approximately 200-fold lower than that of unmodified Ads, and gene expression of the 89% modified PEG-Ad fell by 100 000 or more and was not dose-dependent.

PEG-Ads show high gene expression upon cell entry

We introduced PEG-Ads into cells using Lipofectamine and measured their gene expression in order to verify that the decrease of gene expression of PEG-Ads was derived from




Figure 1. Transduction efficiency of PEGylated adenovirus vectors into A549 cells. A549 cells (2×10^4 cells) were transduced with 300, 1000, 3000 or 10 000 particles/cell of unmodified Ad or PEG-Ad encoding the luciferase gene at the indicated modification ratios. Luciferase expression was measured after 24 h. Each point represents the mean \pm S.D. (n = 3)

binding inhibition due to steric hindrance by PEG chains. The results shown in Figure 2 demonstrated that, in the absence of Lipofectamine, the transduction efficiency of PEG-Ads significantly decreased as PEG modification rate increased. However, in the presence of Lipofectamine, PEG-Ad gene expression at 43% modification was enhanced significantly to nearly that of unmodified Ads. Even at high modification rates (89%), the PEG-Ad gene expression in the presence of Lipofectamine was more than 130-fold higher than that in the absence of Lipofectamine. The gene expression of the heat-inactivated unmodified Ads and the heat-inactivated PEG-Ads were very low even with Lipofectamine. The results




Figure 2. Transduction efficiency of PEGylated adenovirus vectors into A549 cells in the presence or absence of Lipofectamine 2000. A549 cells (2×10^4 cells) were transduced with 1000 particles/cell of unmodified Ad or PEG-Ad in the presence or absence of 20 μ g/ml of Lipofectamine 2000. After 4 h, the virus solution was replaced with fresh medium, and the cells were incubated for 24 h. Luciferase expression was measured. Each point represents the mean \pm S.D. (n = 3). * $P < 0.05$ (Student's t-test)

shown here indicate that high transduction efficiency, which is characteristic of Ads, decreased due to the steric hindrance of CAR by PEG chains.

Construction of PEGylated Ads with RGD peptides

In selecting the adhesion molecule, we focused on the RGD motif, the second mediator of Ad internalization. We constructed RGD-PEG-Ad using RGD-PEG-NHS (Figure 3), which contains two RGD motifs (YGGRGDTP) on the tip of PEG, and we investigated the characteristics of RGD-PEG-Ad (Table 1). RGD-PEG-Ad was 12.5 nm bigger in diameter than unmodified Ads, and the PEG modification rate (36%) was confirmed by SDS-PAGE and NIH Image software.

Enhanced transduction efficiency of RGD-PEG-Ad in comparison to that induced by PEG-Ads

We compared the transduction efficiency of unmodified Ads, PEG-Ads, Ad-RGD, and RGD-PEG-Ad in both A549

Table 1. Modification ratio and vectors size of RGD-PEG-Ad

Ratio (Ad/RGD-PEG)*	PEG modification ratio (%)	Vector size (nm)
1 : 0 (unmodified)	0	122.1 ± 4.5
1 : 250	36	134.6 ± 2.7

*Amount of PEG to lysine residue of adenovirus vector capsid protein (mol/mol)

(CAR-positive) and B16BL6 (CAR-negative) cells. In A549 cells, RGD-PEG-Ad showed 100-fold higher gene expression than PEG-Ad, which exhibits the same level of modification. This gene expression level was similar to that of unmodified Ads and Ad-RGD (Figure 4A). In B16BL6 cells, RGD-PEG-Ad exhibited 60-fold and 200-fold higher gene expression rates than unmodified Ad and PEG-Ad, respectively, but the expression rate was similar to that of Ad-RGD (Figure 4B).

RGD-PEG-Ad specifically infect cells through integrin

The specificity of RGD-PEG-Ad binding via integrin was evaluated by competition assay using the RGD peptide, GRGDTP, which has been widely used as a competitive peptide for integrin [33,34]. In the presence of GRGDTP, RGD-PEG-Ad and Ad-RGD gene expression was remarkably decreased compared to that in the absence of RGD peptide (Figure 5). In contrast, unmodified Ad did not decrease notably, suggesting the introduction of RGD-PEG-Ad was integrin-dependent.

RGD-PEG-Ad maintains its high gene expression in the presence of Ad antiserum

We evaluated transduction efficiency of Ad-RGD and RGD-PEG-Ad in the presence or absence of Ad antiserum using B16BL6 cells. In the presence of Ad antiserum, Ad-RGD gene expression was reduced remarkably. However, RGD-PEG-Ad maintained its high transduction efficiency (Figure 6). In the presence of 125 ng anti-Ad antibody,




Figure 3. Structural scheme for RGD-PEG




Figure 4. Transduction efficiency of RGD-PEGylated adenovirus vectors into A549 cells and B16BL6 cells. (A) A549 (2×10^4) cells and (B) B16BL6 cells (2×10^4) were transduced with 300, 1000, 3000 or 10000 particles/cell of unmodified Ad, PEG-Ad, RGD-PEG-Ad or Ad-RGD, respectively. Luciferase expression was measured after 24 h. Each point represents the mean \pm S.D. ($n = 3$)

RGD-PEG-Ad retained more than one-tenth of its activity, whereas Ad-RGD lost more than 99% of its activity in the absence of antibody.

RGD-PEG-Ad possessed high gene expression *in vivo*

Unmodified Ad, Ad-RGD, and RGD-PEG-Ad mediated luciferase activity predominantly in the liver after intravenous administration. No significant difference in liver transduction was found between unmodified Ad and RGD-PEG-Ad (Figure 7). Biodistribution of Ad-RGD and RGD-PEG-Ad was similar in lung, spleen, kidney, heart and brain (data not shown).

Discussion

Ads are widely used as vectors for gene therapy experiments. To date, several methods including gutless

Ads, which address the decrease in antigenicity [35–37], and fiber mutant Ads [25,38,39], have been developed. In the present study, we initially focused on the modification of Ads by PEG because of its relative ease of development and many other merits such as evasion of neutralizing antibodies. However, as is well known, the conjugation of an Ad with high molecular weight material hinders its interaction with its receptor and subsequently influences the introduction of the virus. Therefore, our aim was to develop novel vectors that exhibit high gene expression while at the same time maintaining the other merits of PEGylated-Ads.

PEGylation of proteins and liposomes has already been widely employed and increased blood stability and mitigation of side effects have been reported [10,11]. PEGylation of the surface of Ads has several advantages. We and other groups have previously demonstrated that modification of an Ad with PEG protects it from neutralizing antibodies [15,16,31]. Likewise, PEGylation has been reported to extend the half-life of Ads in blood




Figure 5. Transduction efficiency of RGD-PEGylated adenovirus vectors in the presence or absence of RGD peptide. B16BL6 cells (2×10^4) were transduced with 3000 particles/cell of unmodified Ad, Ad-RGD or RGD-PEG-Ad in the presence or absence of RGD peptide ($200 \mu\text{g/ml}$). Luciferase expression was measured after 24 h. Each point represents the mean \pm S.D. ($n = 3$). $*P < 0.05$ (Student's t-test)




Figure 6. Transduction efficiency of RGD-PEGylated adenovirus vectors in the presence of adenovirus vector antiserum. B16BL6 cells (2×10^4) were transduced with 1000 particles/cell of RGD-PEG-Ad or Ad-RGD in the presence or absence of Ad antiserum. Luciferase expression was measured after 24 h. Each point represents the mean \pm S.D. ($n = 3$). * $P < 0.05$ (Student's t-test)




Figure 7. The gene expression in liver induced by RGD-PEG-Ad. 1.5×10^{10} particles of unmodified Ad, Ad-RGD, or RGD-PEG-Ad were injected intravenously. After 2 days, the liver was harvested and homogenized. Luciferase activity was then measured using the kit according to the manufacturer's instructions. Each point represents the mean \pm S.D. ($n = 4$)

[17]. Steric hindrance by PEG chains and masking of the Ad surface electric charge were expected to reduce uptake by Kupffer cells. In the present study, we established a method that can control the rate of Ad modification, and the results confirmed that PEGylation notably reduced gene expression efficiency in A549 cells. The data also suggest that increased modification with PEG induced lower gene expression (Figure 1).

In a clinical setting, the most serious problem associated with PEG-Ads is the decrease in transduction. We determined that this decrease results from the inhibition of Ad and CAR interaction due to steric hindrance by PEG chains (Figure 2). This suggests that high gene expression can be achieved if PEGylated-Ads can be transduced into cells. Therefore, in the present study, we focused on the RGD motif, which mediates the entrance of Ads into cells following the interaction with integrin [23,24]. We initially constructed RGD-PEG, which contains the RGD peptide at the tip of PEG, and reacted it with Ad to form

RGD-PEG-Ad. The data in Table 1 demonstrate that the vector size of RGD-PEG-Ad was 12 nm bigger than that of unmodified Ad, and the same tendency was observed in the case of PEG-Ads. The size of Ads increased to about 10–15 nm at a PEG modification rate of 30–40% (data not shown). We thereby succeeded in developing a novel PEG-Ad, the efficacy of which was not influenced by the combination with PEG.

RGD-PEG-Ad gene expression in A549 cells was significantly higher than that of PEG-Ad, and was equivalent to conventional Ad and Ad-RGD (Figure 4). In CAR-negative B16BL6 cells, RGD-PEG-Ad also showed enhanced gene expression, which was much higher than that of PEG-Ads or conventional Ads. Because CAR is expressed at low levels in certain cells, such as hematopoietic stem cells, peripheral blood cells, differentiated airway epithelium, muscle cells, most mouse-derived cells, and many tumor cells, this novel PEGylated Ad is attractive for gene therapy. In addition,

our RGD-PEG-Ad was very stable under -80°C storage conditions, despite several cycles of freezing and thawing (data not shown).

We also checked the specificity of RGD-PEG-Ad infection; we measured the gene expression of unmodified Ad, Ad-RGD, and RGD-PEG-Ad in the presence or absence of competitive RGD peptide (Figure 5). Koizumi *et al.* [25] have already reported the specificity of infection of Ad-RGD through integrin. In the present study, RGD-PEG-Ad gene expression was significantly inhibited by RGD peptide, GRGDTP, and, because RGD-PEG-Ad gene expression in CAR-negative, integrin-positive cells was notably enhanced compared to that of PEG-Ad, we suggest that the transduction of RGD-PEG-Ad was integrin-dependent.

Moreover, we determined whether RGD-PEG-Ad improved resistance to neutralizing antibodies (Figure 6). The expression of Ad-RGD genes fell remarkably in the presence of Ad antiserum. However, we demonstrated that RGD-PEG-Ad gene expression was far higher than that of Ad-RGD in the presence of the antiserum. This ability to evade antibodies is essential for clinical applications because nearly 80% of human patients possess anti-Ad antibodies, and re-administration is indispensable in some cases. Therefore, RGD-PEG-Ad minimizes the amount of medication required and reduces side effects.

The method described here is also applicable to other virus vectors and other target molecules. We are currently screening the use of peptides or antibodies as antigens or tissue-specific targeting molecules using the phage display system. These approaches will promote the development of a virus vector that exhibits enhanced safety and applicability.

Acknowledgements

This study was supported in part by the Research on Health Sciences focusing on Drug Innovation from The Japan Health Sciences Foundation; by Grants-in-Aid for Exploratory Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and by grants from the Ministry of Health and Welfare in Japan.

References

- Gao JQ, Tsuda Y, Katayama K, *et al.* Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. *Cancer Res* 2003; **63**: 4420–4425.
- Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. *Science* 1995; **270**: 404–410.
- Wilson JM. Adenoviruses as gene-delivery vehicles. *N Engl J Med* 1996; **334**: 1185–1187.
- Smith TA, Mehaffey MG, Kayda DB, *et al.* Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. *Nat Genet* 1993; **5**: 397–402.
- Wohlfart C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. *J Virol* 1988; **62**: 2321–2328.
- Mastrangeli A, Harvey BG, Yao J, *et al.* "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. *Hum Gene Ther* 1996; **7**: 79–87.
- Mizuguchi H, Koizumi N, Hosono T, *et al.* A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. *Gene Ther* 2001; **8**: 730–735.
- Yei S, Mittereder N, Tang K, *et al.* Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. *Gene Ther* 1994; **1**: 192–200.
- Croyle MA, Yu QC, Wilson JM. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. *Hum Gene Ther* 2000; **11**: 1713–1722.
- Tsutsumi Y, Tsunoda S, Kamada H, *et al.* Molecular design of hybrid tumour necrosis factor-alpha. II. The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. *Br J Cancer* 1996; **74**: 1090–1095.
- Yoshioka Y, Tsutsumi Y, Ikemizu S, *et al.* Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency. *Biochem Biophys Res Commun* 2004; **315**: 808–814.
- Romanczuk H, Galer CE, Zabner J, *et al.* Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. *Hum Gene Ther* 1999; **1**: 2615–2626.
- Croyle MA, Chirmule N, Zhang Y, *et al.* "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. *J Virol* 2001; **75**: 4792–4801.
- Croyle MA, Chirmule N, Zhang Y, *et al.* PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. *Hum Gene Ther* 2002; **10**: 1887–1900.
- O'Riordan CR, Lachapelle A, Delgado C, *et al.* PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. *Hum Gene Ther* 1999; **10**: 1349–1358.
- Eto Y, Gao JQ, Sekiguchi F, *et al.* Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of MPEG-SPA. *Biol Pharm Bull* 2004; **27**: 936–938.
- Alemanly R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. *J Gen Virol* 2000; **81**: 2605–2609.
- Lanciotti J, Song A, Doukas J, *et al.* Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. *Mol Ther* 2003; **8**: 99–107.
- Ogawara K, Rots MG, Kok RJ, *et al.* A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. *Hum Gene Ther* 2004; **15**: 433–443.
- Bergelson JM, Krithivas A, Celi L, *et al.* The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. *J Virol* 1998; **72**: 415–419.
- Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. *Proc Natl Acad Sci USA* 1997; **94**: 3352–3356.
- Bewley MC, Springer K, Zhang YB, *et al.* Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. *Science* 1999; **286**: 1579–1583.
- Wickham TJ, Mathias P, Cheresch DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. *Cell* 1993; **73**: 309–319.
- Mathias P, Wickham T, Moore M, Nemerow G. Multiple adenovirus serotypes use alpha v integrins for infection. *J Virol* 1994; **68**: 6811–6814.
- Koizumi N, Mizuguchi H, Hosono T, *et al.* Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. *Biochim Biophys Acta* 2001; **1568**: 13–20.
- Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. *Gene Ther* 1999; **6**: 1336–1339.
- Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. *Hum Gene Ther* 1998; **9**: 2577–2583.
- Maizel JV Jr, White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the

- virion and a comparison of types 2, 7A, and 12. *Virology* 1968; **36**: 115–125.
29. Rink H. Solid-phase synthesis of protected peptide fragments using a trialkoxydiphenylmethyl ester resin. *Tetrahedron Lett* 1987; **28**: 3787–3790.
 30. Sieber P. Modification of tryptophan residues during acidolysis of 4-methoxy-2,3,6-trimethylbenzenesulfonyl groups. *Tetrahedron Lett* 1987; **28**: 1637–1641.
 31. Chillon M, Lee JH, Fasbender A, *et al.* Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. *Gene Ther* 1998; **5**: 995–1002.
 32. Xu ZL, Mizuguchi H, Ishii-Watabe A, *et al.* Optimization of transcriptional regulatory elements for constructing plasmid vectors. *Gene* 2001; **11**: 149–156.
 33. Wu ZZ, Li P, Huang QP, *et al.* Inhibition of adhesion of hepatocellular carcinoma cells to basement membrane components by receptor competition with RGD- or YIGSR-containing synthetic peptides. *Biorheology* 2003; **40**: 489–502.
 34. Bronson RA, Fusi F. Evidence that an Arg-Gly-Asp adhesion sequence plays a role in mammalian fertilization. *Biol Reprod* 1990; **43**: 1019–1025.
 35. Hardy S, Kitamura M, Harris-Stansil T, *et al.* Construction of adenovirus vectors through Cre-lox recombination. *J Virol* 1997; **71**: 1842–1849.
 36. Von Seggern DJ, Chiu CY, Fleck SK, *et al.* A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles. *J Virol* 1999; **73**: 1601–1608.
 37. Zou L, Zhou H, Pastore L, Yang K. Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. *Mol Ther* 2000; **2**: 105–113.
 38. Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. *J Virol* 2002; **76**: 8621–8631.
 39. Nicklin SA, Von Seggern DJ, Work LM, *et al.* Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. *Mol Ther* 2001; **4**: 534–542.

Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD')

Masaki Taki¹, Shunsuke Kagawa^{1,2}, Masahiko Nishizaki¹, Hiroyuki Mizuguchi³, Takao Hayakawa³, Satoru Kyo⁴, Katsuyuki Nagai⁵, Yasuo Urata⁵, Noriaki Tanaka¹ and Toshiyoshi Fujiwara^{*,1,2}

¹Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; ²Center for Gene and Cell Therapy, Okayama University Hospital, Okayama 700-8558, Japan; ³Division of Cellular and Gene Therapy Products, National Institute of Health Sciences, Tokyo 158-8501, Japan; ⁴Department of Obstetrics and Gynecology, Kanazawa University School of Medicine, Kanazawa 920-8641, Japan; ⁵Oncolys BioPharma, Inc., Tokyo 106-0031, Japan

Replication-competent oncolytic viruses are being developed for human cancer therapy. We previously reported that an attenuated adenovirus (OBP-301, 'Telomelysin'), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an IRES, could replicate in cancer cells, and causes selective lysis of cancer cells. We further constructed OBP-405 ('Telomelysin-RGD') that contains an RGD motif in the HI loop of the fiber knob. We examined whether OBP-405 could be effective in overcoming the limitations of OBP-301, specifically their inefficient infection into cells lacking the primary receptor, the coxsackievirus and adenovirus receptor (CAR). By flow cytometric analysis, H1299 (lung) and SW620 (colorectal) tumor cells showed high levels of CAR expression, whereas LN444 (glioblastoma), LN2308 (glioblastoma), and H1299-R5 (lung) tumor cells were negative for CAR expression. A quantitative real-time PCR analysis demonstrated that fiber-modified OBP-405 infected more efficiently than OBP-301, although the intracellular replication rate of both viruses was consistent. The comparative antitumor effect of fiber-modified OBP-405 and unmodified OBP-301 for human cancer cells was evaluated *in vitro* by XTT assay as well as *in vivo* by using athymic mice carrying xenografts. OBP-405 had a profound oncolytic effect on human cancer cell lines compared to OBP-301, in particular on cells with low CAR expression. Intratumoral injection of 10⁷ plaque-forming units of OBP-405 into CAR-negative H1299-R5 lung tumor xenografts in *nu/nu* mice resulted in a significant inhibition of tumor growth and long-term survival in all treated mice. Moreover, selective replication of OBP-405 in the distant, uninjected H1299-R5 tumors was demonstrated. Our results suggest that fiber-modified replication-competent adenovirus OBP-405 exhibits a broad target range by increasing infection efficiency, an

outcome that has important implications for the treatment of human cancers.

Oncogene (2005) 24, 3130–3140. doi:10.1038/sj.onc.1208460
Published online 21 February 2005

Keywords: RGD; adenovirus; telomerase; replication; gene therapy

Introduction

The optimal treatment for human cancer requires an improvement of therapeutic ratio to increase cytotoxic efficacy on the tumor cells and decrease that on the normal cells. This may not be an easy task because most of normal cells surrounding tumors are sensitive to the cytotoxic treatment. Thus, to establish reliable therapeutic strategies for human cancer, it is important to seek the genetic and epigenetic targets present only in cancer cells. The emerging fields of functional genomics and functional proteomics provide an expanding repertoire of clinically applicable targeted therapeutics (Kohn *et al.*, 2004). Telomerase is a ribonucleoprotein complex responsible for the addition of TTAGGG repeats to the telomeric ends of chromosomes (Greider and Blackburn, 1985; Collins and Mitchell, 2002), and contains the enzymatic subunit human telomerase reverse transcriptase (hTERT) (Nakamura *et al.*, 1997). The hTERT proximal promoter can be used as a molecular switch for the selective expression of target genes in tumor cells (Koga *et al.*, 2000; Komata *et al.*, 2001; Gu *et al.*, 2000, 2002), since almost all advanced human cancer cells express telomerase and most normal cells do not (Kim *et al.*, 1994; Shay and Wright, 1996). Genetically modified adenoviruses have emerged as a new biological anticancer agent (McCormick, 2001; Fang and Roth, 2003). We previously constructed an adenovirus vector (OBP-301, 'Telomelysin'), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site (IRES), and showed that OBP-301 induced selective

*Correspondence: T Fujiwara, Center for Gene and Cell Therapy, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan; E-mail: toshi_f@md.okayama-u.ac.jp
Received 17 August 2004; revised 22 November 2004; accepted 15 December 2004; published online 21 February 2005

E1A and E1B expression in human cancer cells, but not in normal cells (Kawashima *et al.*, 2004). Therefore, OBP-301 can replicate and lyse only cancer cells, but not normal cells. In addition, OBP-301 will infect neighboring cancer cells, and induce oncolysis throughout the whole tumor mass *in vivo*.

Infection efficiency of the presently available adenoviral agent, which is derived from human adenovirus serotype 5, varies widely depending on the expression of Coxsackie-adenovirus receptor (CAR) (Wickham *et al.*, 1993). The initial step of adenovirus infection involves at least two sequential steps. The first step is the attachment of the virus to the cell surface through binding of the knob domain of the fiber to CAR (Bergelson *et al.*, 1997). Following attachment, the viral internalization into the cells occurs by the interaction of RGD (Arg-Gly-Asp) motifs of penton base with integrin receptors, $\alpha v\beta 3$ and $\alpha v\beta 5$, expressed on most cell types (Wickham *et al.*, 1993). Therefore, the interaction of the fiber knob with CAR on the cell is the key mediator by which adenoviral agents enter the cells. Modification of fiber protein is an attractive strategy for overcoming the limitations imposed by the CAR dependence of adenovirus infection (Wickham *et al.*, 1997; Dmitriev *et al.*, 1998; Krasnykh *et al.*, 1998; Mizuguchi *et al.*, 2001).

We modified the fiber of OBP-301 to contain RGD peptide, which binds with high affinity to integrins ($\alpha v\beta 3$ and $\alpha v\beta 5$) on the cell surface, on the HI loop of the fiber protein. The resultant adenovirus, termed OBP-405 or 'Telomelysin-RGD', mediated not only CAR-dependent virus entry but also CAR-independent, RGD-integrin ($\alpha v\beta 3$ and $\alpha v\beta 5$)-dependent virus entry. We explored whether OBP-405 containing RGD peptide on the fiber knob had more oncolytic efficacy on several types of human cancer cells (CAR-positive or -negative), as compared with OBP-301 containing wild-type fiber *in vitro* and *in vivo*.

Results

Expression of CAR and integrins in human cancer and normal cells

To investigate the antitumor effect of the fiber-modified OBP-405, we used several human cell lines. We first examined the expression levels of CAR and αv integrin family, $\alpha v\beta 3$ and $\alpha v\beta 5$, on each cell surface by flow cytometric analysis (Figure 1). Apparent amounts of CAR expression were detected on H1299 and SW620 cells, whereas LN444, LN308, and H1299-R5 cells expressed extremely low levels of CAR. The normal human lung fibroblast (NHLF) cell also exhibited detectable CAR expression. In contrast to CAR, $\alpha v\beta 3$ and $\alpha v\beta 5$ integrins were readily expressed in all cell lines.

Increased infection efficiency and selective replication of OBP-405

To assess whether incorporation of an RGD motif into the HI loop of the fiber knob domain would enhance its

infectivity, CAR-positive parental H1299, CAR-negative LN444, and NHLF (normal cell) were infected with OBP-301 or OBP-405 at an multiplicity of infection (MOI) of 1. Quantitative real-time PCR analysis with DNA extracted 2 h after infection demonstrated that the amount of E1A DNA after OBP-405 infection was higher than that after OBP-301 infection in two human cancer cell lines, whereas infectivity of both viruses was almost similar in NHLF (Figure 2a). These results suggest that RGD-modified OBP-405 showed increased infectivity to neoplastic cells regardless of the levels of CAR expression, although the infectivity enhancement was greater in CAR-negative cancer cells.

We next examined the replication ability of OBP-301 and OBP-405 in different cell lines by measuring the relative amounts of E1A DNA. H1299, LN444, and NHLF cells were harvested at the indicated time points over 72 h after infection with OBP-301 or OBP-405, and subjected to quantitative real-time PCR analysis. The ratios were normalized by dividing the value of cells obtained 2 h after viral infection. As shown in Figure 2b, both OBP-301 and OBP-405 replicated 5–6 logs by 72 h after infection; their replication, however, were attenuated up to 3 logs in normal NHLF cells.

Enhanced viral spread of OBP-405 in human cancer cells

To examine whether increased infectivity of OBP-405 could facilitate viral spread, H1299, LN444, and NHLF cells cultured in chamber slides were infected either with OBP-301 or OBP-405 at an MOI of 1, and then immunohistochemically stained for viral hexon at 24 and 48 h of postinfection. Viral hexon was detectable in H1299 cells infected with OBP-301 and OBP-405 in a time-dependent manner, although the amount of positive cells after OBP-405 infection was higher than that after OBP-301 infection (Figure 3a). In contrast, viral hexon was only present in CAR-negative LN444 cells infected with OBP-405, but not in OBP-301-infected LN444 cells (Figure 3b), suggesting the selective replication of OBP-405 in CAR-negative human cancer cells. NHLF human normal cells exhibited no hexon-positive cells after OBP-301 or OBP-405 infection (Figure 3c).

In vitro cytopathic efficacy of OBP-405 in CAR-negative human cancer cells

To test whether the increased infectivity and replication of OBP-405 translated to improved oncolysis, we compared the cytopathic effect of OBP-405 with that of OBP-301 on various human cell lines *in vitro* (Figure 4). Both OBP-301 and OBP-405 killed CAR-positive H1299 and SW620 human cancer cells in a dose-dependent manner; OBP-405 at an MOI of 0.1, however, killed these cells as efficiently as OBP-301 at an MOI of 1, suggesting that OBP-405 showed approximately 10-fold more profound tumor cell killing compared with OBP-301. In contrast, only OBP-405 was lytic in CAR-negative LN444, LN308, and H1299-R5 cells, likely due to the higher infectivity of OBP-405




Figure 1 Flow cytometric analysis of CAR and integrin ($\alpha v\beta 3$ and $\alpha v\beta 5$) expression in human cancer and normal cell lines. Cells were incubated with anti-CAR (RmcB), anti- $\alpha v\beta 3$ integrin (LM609), and anti- $\alpha v\beta 5$ integrin (PIF6) monoclonal antibodies, followed by detection with FITC-labeled goat anti-mouse IgG secondary antibody. An isotype-matched normal mouse IgG1 conjugated to FITC was used as a control in all experiments (solid line)

in these cell lines. Most of these cells were dead within 5 days after OBP-405 infection, whereas OBP-301-infected cells were still intact at 5 days postinfection (Figure 4b). Neither OBP-301 nor OBP-405 exhibited cytopathic effect on NHLF cells.

Enhanced oncolysis of CAR-negative tumor xenografts by OBP-405

We next examined whether OBP-405 cause enhanced oncolysis and spread *in vivo*. Subcutaneous H1299-R5 tumor xenografts with a diameter of 5–6 mm received three daily courses of intratumoral injection of 1×10^7 plaque-forming units (PFU) of OBP-301, OBP-405 or replication-deficient control adenovirus (dl312), or PBS (mock). As shown in Figure 5, administration of OBP-405 resulted in significant growth suppression compared to mock- or dl312-treated tumors 34 days after virus

injection ($P < 0.01$). In addition, one of the six mice treated with OBP-405 showed the complete eradication of the established H1299-R5 tumor. We previously reported that intratumoral injection of OBP-301 significantly inhibited the growth of H1299 tumor xenografts; a modest, insignificant growth inhibition, however, occurred with administration of OBP-301 on H1299-R5 tumors. Treatment with replication-deficient dl312 had no apparent effect on the growth of H1299-R5 tumors.

Targeting replication of OBP-405 in tumor tissues in vivo

To evaluate selective replication of OBP-301 and OBP-405 *in vivo*, we examined mouse tissues including implanted tumors for the presence of viral DNA and protein by quantitative real-time PCR and immunohistochemistry, respectively, following intratumoral viral